Not Yet RecruitingNot Applicable

Modified Double Snare Assisted EMR (mDS-EMR) VS ESD for Rectal Neuroendocrine Tumors Smaller Than 1cm

118 participantsStarted 2026-01-01

Plain-language summary

The aim of this study is evaluating and safety and efficacy between the modified double snare EMR and ESD. It is intended to prove that for rectal neuroendocrine tumors within 1 cm, the complete resection rate of the mDS-EMR is not inferior to that of ESD, but may with shorter operation time, lower complication rate and lower treatment cost.

Who can participate

Age range18 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Typical rectal neuroendocrine tumors by endoscopy (within 15cm from the anal verge, yellowish subepithelial elevation with a smooth surface, and dilated blood vessels in some areas).
✓. The maximum diameter of the lesion is smaller than 1cm by preoperative endoscopic assessment.
✓. Lesion is located within the mucosal and submucosal layer by preoperative endoscopic assessment.
✓. Patients can understand and sign the informed consent.

Exclusion criteria

✕. Poor coagulation function(PT\>15 seconds or APTT\>45 seconds or INR\>2.0)
✕. With severe cardiovascular or cerebrovascular diseases and cannot tolerate operation( with a history of stroke or myocardial infarction within the past month or with severe heart failure and cardiac function grade III)
✕. Indication of metastasis by preoperative imaging examinations
✕. With more than or equal to 2 rectal neuroendocrine tumors
✕. With other complications that are not suitable for this study by multidisciplinary team assesment
✕. Cases of recurrence after operation for neuroendocrine tumors

What they're measuring

complete resection

Timeframe: Day 30

Trial details

NCT IDNCT07373015

SponsorThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2028-05-31

View on ClinicalTrials.gov More Rectal Neuroendocrine Tumors trials